Atrial Structural Remodeling Gene Variants in Patients with Atrial Fibrillation

Figure 4

AKAP9 is required for myonuclear positioning in C2C12 myotubes. (a) Representative immunofluorescence images of control (no transfection and Scramble siRNA treated cells) or AKAP9-depleted C2C12 myotubes (using 3 individual siRNA, 30 nM each) differentiated for 5 days and immunostained for myosin heavy chain (green) and 49,6-diamidino-2-phenylindole (red). Scale bar, 160 um. (b) 7× magnifications of rectangles shown in images (a). Scale bar, 160 um. (c) Histogram of percentage of total C2C12 myotubes with aggregated nuclei control (no transfection and Scramble siRNA treated cells) or AKAP9-depleted C2C12 myotubes (using 3 individual siRNA, 30 nM each) differentiated for 5 days. Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by R software; whiskers extend to 5th and 95th percentiles, outliers are represented by dots; width of the boxes is proportional to the square root of the sample size; data points are plotted as open circles. n = 6, 12, 9, 9, 7 sample points. Student’s t-tests were performed between scrambled siRNA and experimental condition. Asterisk, P, 0.05; two asterisks, P, 0.01; ns: nonsignificant.

(a)

(b)

(c)